Zenas BioPharma (NASDAQ:ZBIO – Get Free Report) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.
Valuation & Earnings
This table compares Zenas BioPharma and Kiniksa Pharmaceuticals International”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Zenas BioPharma | $1.00 million | 1,619.00 | -$377.74 million | ($8.99) | -2.76 |
| Kiniksa Pharmaceuticals International | $840.85 million | 7.29 | $59.01 million | $0.97 | 81.02 |
Kiniksa Pharmaceuticals International has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current ratings and recommmendations for Zenas BioPharma and Kiniksa Pharmaceuticals International, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Zenas BioPharma | 1 | 2 | 6 | 0 | 2.56 |
| Kiniksa Pharmaceuticals International | 0 | 1 | 8 | 0 | 2.89 |
Zenas BioPharma presently has a consensus target price of $46.71, suggesting a potential upside of 88.06%. Kiniksa Pharmaceuticals International has a consensus target price of $93.14, suggesting a potential upside of 18.52%. Given Zenas BioPharma’s higher probable upside, equities analysts plainly believe Zenas BioPharma is more favorable than Kiniksa Pharmaceuticals International.
Risk & Volatility
Zenas BioPharma has a beta of -0.9, suggesting that its share price is 190% less volatile than the S&P 500. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.04, suggesting that its share price is 96% less volatile than the S&P 500.
Institutional and Insider Ownership
54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. 22.0% of Zenas BioPharma shares are held by insiders. Comparatively, 52.0% of Kiniksa Pharmaceuticals International shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Zenas BioPharma and Kiniksa Pharmaceuticals International’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Zenas BioPharma | N/A | -122.45% | -58.04% |
| Kiniksa Pharmaceuticals International | 9.59% | 13.65% | 10.09% |
Summary
Kiniksa Pharmaceuticals International beats Zenas BioPharma on 12 of the 14 factors compared between the two stocks.
About Zenas BioPharma
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.
About Kiniksa Pharmaceuticals International
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.
Receive News & Ratings for Zenas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zenas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
